Junshi Announces $1.1 Billion Agreement for US-Canada Rights to PD-1

Shanghai Junshi Bio out-licensed US-Canada rights for its anti-PD-1 antibody to Coherus Bio in an agreement worth up to $1.1 billion. Coherus will pay $150 million upfront. Coherus also received options for an anti-TIGIT antibody and a next-gen engineered IL-2 cytokine, as well as first negotiation rights for two early-stage checkpoint inhibitor antibodies. Junshi's Tuoyi (toripalimab) is the first China-developed anti-PD-1 antibody approved in China . More details.... Stock Symbols: (HK: 1877; SHA: 688180)  (NSDQ: CHRS) Share this with colleagues: // //